Literature DB >> 24178797

Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.

Tatiana D Gonçalves1, Rodrigo A Toledo, Tomoko Sekiya, Sergio E Matuguma, Fauze Maluf Filho, Manoel S Rocha, Sheila A C Siqueira, Andrea Glezer, Marcelo D Bronstein, Maria A A Pereira, Ricardo Jureidini, Telesforo Bacchella, Marcel C C Machado, Sergio P A Toledo, Delmar M Lourenço.   

Abstract

CONTEXT: Data are scarce on the penetrance of multiple endocrine neoplasia type 1 (MEN1)-related nonfunctioning pancreatic neuroendocrine tumors (NF-PETs) and insulinomas in young MEN1 patients. A potential positive correlation between tumor size and malignancy (2-3 cm, 18%; >3 cm, 43%) has greatly influenced the management of MEN1 adults with NF-PETs.
OBJECTIVE: The aim of the study was to estimate the penetrance of NF-PETs, insulinomas, and gastrinomas in young MEN1 carriers.
DESIGN: The data were obtained from a screening program (1996-2012) involving 113 MEN1 patients in a tertiary academic reference center. PATIENTS: Nineteen MEN1 patients (aged 12-20 y; 16 patients aged 15-20 y and 3 patients aged 12-14 y) were screened for NF-PETs, insulinomas, and gastrinomas.
METHODS: Magnetic resonance imaging/computed tomography and endoscopic ultrasound (EUS) were performed on 10 MEN1 carriers, magnetic resonance imaging/computed tomography was performed on five patients, and four other patients underwent an EUS.
RESULTS: The overall penetrance of PETs during the second decade of life was 42% (8 of 19). All eight PET patients had NF-PETs, and half of those tumors were multicentric. One-fifth of the screened patients (21%; 4 of 19) harbored at least one large tumor (>2.0 cm). Insulinoma was detected in two NF-PET patients (11%) at the initial screening; gastrinoma was not present in any cases. Six of the 11 (54%) screened patients aged 15-20 years who underwent an EUS had NF-PETs. Potential false-positive EUS results were excluded based on EUS-guided biopsy results, the reproducibility of the NF-PET findings, or the observation of increased tumor size during follow-up. Distal pancreatectomy and the nodule enucleation of pancreatic head tumors were conducted on three patients with large tumors (>2.0 cm; T2N0M0) that were classified as grade 1 neuroendocrine tumors (Ki-67<2%).
CONCLUSIONS: Our data demonstrated high penetrance of NF-PETs in 15- to 20-year-old MEN1 patients. The high percentage of the patients presenting consensus criteria for surgery for NF-PET alone or NF-PET/insulinoma suggests a potential benefit for the periodic surveillance of these tumors in this age group.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24178797     DOI: 10.1210/jc.2013-1768

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 3.  Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Authors:  Jonathan D Wasserman; Gail E Tomlinson; Harriet Druker; Junne Kamihara; Wendy K Kohlmann; Christian P Kratz; Katherine L Nathanson; Kristian W Pajtler; Andreu Parareda; Surya P Rednam; Lisa J States; Anita Villani; Michael F Walsh; Kristin Zelley; Joshua D Schiffman
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

4.  MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors.

Authors:  Letizia Vannucci; Francesca Marini; Francesca Giusti; Simone Ciuffi; Francesco Tonelli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2017-05-22       Impact factor: 3.633

5.  Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience.

Authors:  Kira Oleinikov; Inbal Uri; Harold Jacob; Julia Epshtein; Ariel Benson; Simona Ben-Haim; Karine Atlan; Ilanit Tal; Amichay Meirovitz; Ofra Maimon; Naama Lev-Cohain; Haggi Mazeh; Benjamin Glaser; David J Gross; Simona Grozinsky-Glasberg
Journal:  Endocrine       Date:  2020-02-08       Impact factor: 3.633

6.  Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?

Authors:  Jerena Manoharan; Friedhelm Raue; Caroline L Lopez; Max B Albers; Carmen Bollmann; Volker Fendrich; Emily P Slater; Detlef K Bartsch
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

7.  The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.

Authors:  Federica Cioppi; Luisella Cianferotti; Laura Masi; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

8.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 9.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

10.  Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Authors:  Wei Qiu; Ioannis Christakis; Angelica Silva; Roland L Bassett; Liyun Cao; Qing H Meng; Elizabeth Gardner Grubbs; Hua Zhao; James C Yao; Jeffrey E Lee; Nancy D Perrier
Journal:  Clin Endocrinol (Oxf)       Date:  2016-06-30       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.